Goldman Sachs’ downgrade of China Feihe to Neutral reads as more than a single-stock call. It is a marker for how offshore China is recalibrating consumer defensives in a slow-growth, tariff-shadowed environment. With a weaker IMF-style growth backdrop and Goldman now projecting China’s GDP at roughly 4 percent in 2025 and 3.5 percent in 2026 amid higher US tariffs, the infant formula leader sits at the intersection of two structural drags: a shrinking birth cohort and pressure on household spending. The signal for Hong Kong-listed consumer names is clear: quality franchises remain investable, but reratings will be earned, not granted.
Goldman has been explicit about an onshore-offshore split: cautious on Hong Kong-traded Chinese equities while keeping a constructive view on mainland A-shares linked to strategic themes such as artificial intelligence. That bifurcation matters for Feihe, which is listed in Hong Kong and priced by a foreign investor base that has demanded faster earnings delivery and higher cash returns. The bank still sees scope for a double-digit rally in broad A-shares, calling for the CSI 300 to reach around 4,600 with policy easing and better earnings. But that optimism does not automatically extend to offshore consumer staples facing weaker external sentiment and tighter valuation discipline.
Feihe’s fundamentals are tied to demographics no brand can outrun. National Bureau of Statistics data show births fell to roughly 9 million in 2023, continuing the decline that began pre-pandemic. Provincial policies subsidizing childbirth and childcare have produced uneven results so far. The 14th Five-Year Plan flags population quality and family services, but the demand curve for infant formula is set by cohort size and purchase frequency. Premiumization helped the sector in the past decade, but with fewer infants and heightened price sensitivity among new parents, unit elasticity is moving the wrong way. Even leaders with strong distribution and localized branding are working harder to keep volumes flat, and pricing power is no longer a given.
Regulation has reinforced consolidation. New national standards and the re-registration regime for infant formula enforced by the State Administration for Market Regulation in 2023 raised the bar on formulations and labeling, reducing the number of approved products and squeezing smaller players. Authorities have also tightened marketing practices around hospitals in line with Healthy China goals and breastfeeding promotion. The official stance is clear: higher quality, fewer SKUs, and stricter compliance. For scale incumbents like Feihe, that is a moat, but it comes with higher R&D and compliance costs and less room for aggressive promotional tactics. The policy intent is consumer protection, not profit protection, which means margins must be earned through efficiency and product trust.
The distribution side remains fragile. Inventory overhang from the pandemic era has been slow to clear in lower-tier cities. Live-stream and group-buy channels, led by platforms such as Douyin and Pinduoduo, have compressed channel margins across fast-moving consumer goods. That erodes the advantage of traditional mother-and-baby store networks, a core pillar for domestic formula brands. Promotional intensity has risen, and while companies can protect reported average selling prices for a period, the trade-off shows up in sell-in volatility and rebate accruals. In past cycles, share gains against foreign brands offset pricing pressure. Today, with household budgets under strain and competition from cost-effective private labels online, the balance is less favorable.
Macro policy is supportive in theory. The Central Economic Work Conference and NDRC’s recent consumption guidance continue to emphasize household spending recovery, services, and childcare infrastructure. The outline for expanding domestic demand through 2035 highlights mother-and-infant goods as a stable consumption category. Yet the policy mix has leaned toward supply-side and investment-heavy supports. Structural reforms that lift household disposable income—such as social security portability, lower out-of-pocket education costs, and hukou liberalization in large cities—move slowly. SOE reform, a core Five-Year Plan theme, channels capital toward strategic sectors, not necessarily household balance sheets. The result is a floor under growth, not a catalyst for a consumer upcycle that would float all staples boats.
Goldman expects fiscal easing and further monetary support, including possible reserve ratio and interest rate cuts, to cushion tariff impacts. That can help funding costs and risk appetite across the market. But for staples like infant formula, the binding constraint is demand formation, not the cost of capital. Lower rates do not create babies. They may, however, support valuation multiples if earnings are stable. Here, the earnings trajectory is the swing factor. Consensus assumes margin resilience as the SAMR clean-up benefits leaders, with cost tailwinds from lower whole milk powder prices. The risk is that price competition intensifies in online channels and that marketing spend must rise to defend share, offsetting input savings. Offshore funds are voting to wait for evidence in reported numbers rather than paying ahead.
Three datapoints will separate signal from noise. First, volume trends by tier of city and channel mix will show whether sell-through is stabilizing. Second, gross-to-net reconciliation and changes in distributor incentives will reveal the true cost of defending shelf space. Third, cash conversion and buyback pace will test capital discipline in a low-growth environment. From a policy angle, watch for any incremental fertility support at the provincial level in the second half and for additional steps under the childcare service development plan. On the trade front, escalation in US-China tariffs beyond what is already assumed would add another headwind to income expectations via export-linked jobs, even if indirect for domestic staples.
The downgrade underscores a broader valuation regime for Hong Kong-listed consumer names. Investors are rewarding hard catalysts—cost cuts, asset sales, buybacks—over narratives. Companies with visible cash yields and de-risked earnings are holding up better. Those more reliant on macro recovery or policy impulse are trading at a discount. For Feihe and peers, execution on premium SKUs, channel modernization, and disciplined spending will matter more than top-down consumption targets. The offshore market will not pay for the policy story alone. Meanwhile, A-shares tied to industrial upgrading and AI remain the preferred policy proxies, consistent with Goldman’s split view.
Feihe remains a franchise with scale, local trust, and regulatory tailwinds from consolidation. But the investment debate has shifted from share gains to absolute demand. Goldman’s Neutral is a reminder that in today’s China, defensives are not immune to structural drags. Policy easing can stabilize the backdrop and lift onshore risk appetite, yet it will not rewrite demographics or household budgets quickly. For investors, the bar is rising: insist on cash, proof of pricing power in digital channels, and alignment with policy without relying on it. In a market favoring clarity over hope, staples with real moats will still find buyers—but only at the right price.
